Slide 1: Managing Director Report
Managing Director Report 6 Months to 31 Jan 2021 16 March 2021
Slide 2: Vision, Values & Purpose
Vision, Values & Purpose Vision To optimise the health and development of adults, infants and children. Values Respect, Response, Responsibility Purpose In collaboration with key market participants, Clover develop customised high value nutritional ingredients that enhance the wellbeing and dietary
Slide 3: COVID-19 Update
COVID-19 Update Clover has maintained a focus on the health and safety of staff, implementing COVID safe plans, and staff have worked from home where possible Clover has not sought or received any government assistance Clover ’s H1FY21 result has been negatively impacted by global COVID‐19 • M
Slide 4: Half-Year Performance
Half-Year Performance Operating Revenue Interim fully franked $29.4m down dividend 21.7% on half year 2020 0.5c/share declared Net Profit $2.5m down 1H21 v 1H20 revenue improvements from Asia, 45.8% on half year 2020 USA & Europe under difficult market conditions Operating expenses of In
Slide 5: Half-Year 2021 Results
Half-Year 2021 Results AUD million 31 Jan 2021 31 Jan 2020 • Revenue declined 21.7% impacted by demand and FX Revenue $29.4 $37.6 (like for like FX, Revenue of $30.3m) NPBT $3.3 $6.4 Tax ($0.8) ($1.7) • NPAT result $2.5m (PCP $4.6m), expenses have been curtailed NPAT $2.5 $4.6 with a focus on discre
Slide 6: Balance Sheet
Balance Sheet 31 January 2021 AUD million Reported Reported Movement 31 Jan 2021 31 Jul 2020 Cash $9.8 $9.2 $0.6 • Cash position Trade $9.7 $16.8 ($7.1) remains strong Receivables Inventories $31.5 $31.9 ($0.4) • Inventories Total Current $52.1 $59.1 ($7.0) maintained to meet Assets future demand Fi
Slide 7: Sales by Geography
Sales by Geography 1H20 SALES BY MARKET Demand from Australia & New Americas Europe 6% Zealand has been impacted by 11% COVID‐19 & Daigou reductions Asia demand improved marginally from new product applications Asia Australia/NZ 56% European sales growth from new 27% customers (with historical
Slide 8: An Update on Growth Platforms
An Update on Growth Platforms Focus on Infant Formula New New Product Market Development Development 5
Slide 9: Growth Platform: Customer development in infant formula
Focus on Infant Formula Growth Platform Customer development in infant formula New infant formula customers added in the half year in the EU with others requiring audit of our facilities before progressing Key customers impacted by reduced demand from China due to COVID-19 restrictions, reduced
Slide 10: Growth Platform: Creating new opportunities
Growth Platform Creating new opportunities A highly concentrated Omega 3 powder released during the first half is in product application trials in food & nutraceutical products Sales across food & beverage products increased in the half A solutions-based training program delivered on electroni
Slide 11: Growth Platform: Expanding our market reach
Growth Platform Expanding our market reach Continued push for growth in EU, Asia and Americas New Business development staff established across EU, China & USA, where face to face customer visits are not possible Trade shows have moved online with little success Clover’s new spray dryer buil
Slide 12: 2HFY2021 Outlook & Priorities
2HFY2021 Outlook & Priorities • Continue to develop opportunities in the EU, USA & Asia • Complete qualification of Melody Dairies NZ spray dryer • Establish additional raw material sources • Further develop Chinese infant formula relationships to prepare for the proposed new manufacturing standard
Slide 13: Disclaimer
Disclaimer The release, publication or distribution of this presentation in certain jurisdictions may be restricted by law and therefore persons in such jurisdictions into which this presentation is released, published or distributed should inform themselves about and observe such restrictions. This